TGF-α and IL-6 plasma levels selectively identify CML patients who fail to achieve an early molecular response or progress in the first year of therapy

Eva Nievergall,John V. Reynolds,Chung H. Kok,Dale B. Watkins,Mark Biondo,Samantha J. Busfield,Gino Vairo,Kathy A. Fuller,Wendy N. Erber,Teresa Sadras,R Grose,D.T. T. Yeung,Angel F. Lopez,Devendra K Hiwase,Timothy P. Hughes,Deborah L. White

TGF-α and IL-6 plasma levels selectively identify CML patients who fail to achieve an early molecular response or progress in the first year of therapy

2016

Eva Nievergall
John V. Reynolds
Chung H. Kok
Dale B. Watkins
Mark Biondo
Samantha J. Busfield
Gino Vairo
Kathy A. Fuller
Wendy N. Erber
Teresa Sadras
R Grose
D.T. T. Yeung
Angel F. Lopez
Devendra K Hiwase
Timothy P. Hughes
Deborah L. White

TGF-α and IL-6 plasma levels selectively identify CML patients who fail to achieve an early molecular response or progress in the first year of therapy

Keywords:

Lymphoma
Molecular Response
Cancer research
Leukemia
Stem cell
Hematology
TGF alpha
Interleukin 6
Internal medicine
Haematopoiesis
Medicine
Biomarker (medicine)
Immunology
Tyrosine-kinase inhibitor
Oncology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations